XOMA Corp
$ 25.94
0.31%
24 Feb - close price
- Market Cap N/A
- Current Price $ 25.94
- High / Low $ 25.94 / 25.76
- Stock P/E 25.91
- Book Value 7.14
- EPS 1.00
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.22 %
- 52 Week High 28.80
- 52 Week Low 23.47
About
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and Asia Pacific. The company is headquartered in Emeryville, California.
Analyst Target Price
N/A
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-13 | 2025-05-13 | 2025-03-17 | 2023-05-09 | 2023-03-09 | 2022-11-03 | 2022-08-04 | 2022-05-05 | 2022-03-08 | 2021-11-04 | 2021-08-05 |
| Reported EPS | 0.7 | 0.44 | 0.06 | -0.45 | -0.98 | -0.64 | -0.48 | -0.53 | -0.32 | 1.69 | -0.51 | -0.31 |
| Estimated EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise | 0.7 | 0.44 | 0.06 | -0.45 | -0.98 | -0.64 | -0.48 | -0.53 | -0.32 | 1.69 | -0.51 | -0.31 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-01-15 | 2025-10-15 | 2025-07-15 | 2025-04-15 | 2025-01-15 | 2024-10-15 | 2024-07-15 | 2024-04-15 | 2024-01-16 | 2023-10-16 |
| Amount | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 | $0.53906 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XOMAP
2026-02-20 01:57:47
XOMA Royalty Corporation has entered into a definitive merger agreement to acquire Turnstone Biologics Corp. for $0.34 in cash per share, plus a non-transferable contingent value right, with the transaction expected to close in August 2025. The Turnstone Board of Directors unanimously approved the acquisition, and a significant portion of Turnstone stockholders have agreed to support the merger. This acquisition is part of XOMA's strategy to expand its biotechnology royalty portfolio.
2026-02-20 01:39:15
XOMA Royalty Corporation (XOMA) offers a compelling investment opportunity in the biotechnology sector through its unique royalty aggregation model. The company acquires rights to milestone and royalty payments from various therapeutic candidates, enabling it to benefit from successful commercial and clinical assets. Analysts project a significant upside potential of 164.89% for XOMA's stock, driven by its robust revenue growth and strategic acquisitions, despite current negative free cash flow.
2026-02-09 09:53:00
XOMA Royalty Corporation has successfully completed its tender offer and acquisition of Generation Bio Co. for $4.2913 per share in cash plus a contingent value right. Approximately 70% of Generation Bio's outstanding shares were tendered, satisfying the minimum conditions. As a result, Generation Bio is now a wholly-owned subsidiary of XOMA Royalty and its shares have ceased trading on Nasdaq, with plans for delisting and deregistration.
2026-02-07 21:01:25
XOMA Royalty Corporation has successfully completed its tender offer and acquisition of Generation Bio Co. for $4.2913 per share in cash plus a contingent value right. The tender offer closed on February 6, 2026, with approximately 70% of Generation Bio's outstanding shares tendered. Generation Bio is now a wholly-owned subsidiary of XOMA Royalty, and its shares have ceased trading on Nasdaq and will be delisted.
2026-01-23 14:27:32
Pomerantz LLP is investigating potential securities fraud claims against XOMA Royalty Corporation (NASDAQ: XOMA) on behalf of its investors. This investigation follows the announcement by Xoma's development partner, Rezolute, Inc., that its Phase 3 sunRIZE study evaluating ersodetug failed to meet its primary and key secondary endpoints, leading to a significant drop in Xoma's stock price. Investors are encouraged to contact Pomerantz LLP for information on potentially joining a class action lawsuit.
2026-01-12 12:28:12
XOMA Royalty Corporation announced that its CFO, Thomas Burns, is stepping down to pursue other professional opportunities after nearly two decades of service. Jeffrey Trigilio has been appointed as the new Chief Financial Officer, bringing extensive experience from various financial and strategic roles in biotech and investment banking. The company highlighted its strong financial foundation and robust portfolio of commercial assets and royalty streams, with the new CFO aiming to continue a strategy of disciplined capital deployment and innovative deal structuring.
